亚太地区心血管代谢疾病市场预测至 2028 年 - COVID-19 影响和按类型（心血管疾病 (CVD)、2 型糖尿病、高血压和肥胖）、治疗（ACE 抑制剂、利尿剂、格华止等）、剂量（片剂和注射剂）、给药途径（口服和静脉注射）、最终用户（医院、诊所和家庭护理机构）和分销渠道（医院药房、零售药房和在线药房）

市场介绍

心脏代谢疾病的特点是一组异常和症状，这些异常和症状会引起个人患心血管疾病的风险。高血压、肥胖、胰岛素抵抗、血脂异常、胆固醇水平 (LDL) 不良和葡萄糖耐量是其中一些症状。患有心脏代谢综合征的人容易患上其他几种危及生命的疾病，例如 2 型糖尿病、中风、冠状动脉疾病 (CAD)、心血管疾病 (CVD) 等。

此外，心脏代谢疾病的日益流行预计将推动预测期内的市场增长。然而，中低收入国家 (LMIC) 对心血管疾病的诊断不足限制了亚太地区心脏代谢疾病市场的增长。

供应链中断和对心血管代谢疾病的巨大需求COVID-19 的有效治疗方法使亚太地区的医疗保健研究行业处于至关重要的境地。已采取禁止性措施来控制这一流行病的蔓延。 COVID-19 大流行广泛影响了亚太地区的经济体。印度（31,769,132）、日本（956,407）、中国（93,289）、韩国（203,926）等国家受到疫情的不利影响。社会经济受到严重影响，负通胀、国内生产总值上升，地区失业率激增。近年来，日本高血压和肥胖症患者不断增加。这些患者罹患 COVID-19 重症的风险极高，因此需要仔细观察和强化治疗。与高血压相比，肥胖的定义在不同的研究/国家中并不一致，这需要考虑。但值得注意的是，CCB针对COVID-19的治疗机制仍有待进一步研究和随机对照临床试验。

市场概况及动态

亚太地区心脏代谢疾病市场预计将从2021年的210.913亿美元增至2028年的289.532亿美元；预计 2021 年至 2028 年复合年增长率为 4.6%。心脏代谢疾病 (CMD) 是全球主要死亡原因之一。这些疾病主要是由不健康的生活方式、缺乏运动、吸烟和不健康的饮食引起的。 CMD 包括心血管疾病 (CVD)、糖尿病和慢性肾功能衰竭。大多数心血管疾病可以通过解决行为危险因素来预防，例如烟草摄入、不健康的饮食选择、肥胖、缺乏身体活动和饮酒。糖尿病是危及生命的慢性疾病之一，尚无功能性治愈方法。它会导致各种并发症并增加过早死亡的总体风险。心脏病、中风、肾衰竭、截肢、视力丧失和神经损伤是与糖尿病相关的主要并发症。由于吸烟、缺乏运动、饮酒和不健康的饮食习惯的增加，患有一种或多种 CMD 的人数有所增加。肥胖症患病率的增加也导致了患有 CMD 的患者群体的增加。随着 CMD 患病率的迅速上升，对适当的心脏代谢疾病治疗的需求猛增，从而导致亚太地区心脏代谢疾病市场的巨大增长。

< u>主要细分市场

从类型来看，心血管疾病细分市场在2020年亚太心脏代谢疾病市场中占据最大份额就治疗而言，ACE抑制剂细分市场占据2020年亚太心脏代谢疾病市场最大份额；就剂量而言，片剂细分市场占据2020年亚太心脏代谢疾病市场最大份额。从给药途径来看，口服细分市场在 2020 年亚太心脏代谢疾病市场中占据最大份额。从最终用户来看，医院细分市场在 2020 年亚太心脏代谢疾病市场中占据最大份额。从分销渠道来看，医院药房细分市场2020年市场份额最大。

主要来源及上市公司

u>
准备本亚太地区心脏代谢疾病市场报告时提到的一些主要一手和二手来源是公司网站、年度报告、财务报告、国家政府文件、统计数据库等。报告中列出的主要公司包括礼来公司、拜耳公司、诺华公司、勃林格殷格翰国际有限公司、诺和诺德公司、阿斯利康、Cardax Inc.和Kowa Company, Ltd.

购买报告的理由
了解亚太地区心脏代谢疾病市场格局，并确定可能保证丰厚回报的细分市场
了解不断变化的市场格局并保持领先地位在竞争中处于领先地位
通过识别最有可能销售前景的细分市场，有效规划亚太心脏代谢疾病市场的并购和合作伙伴交易
通过对各个细分市场的市场表现进行敏锐而全面的分析，做出明智的业务决策
获得亚太地区的市场收入预测2021-2028年按不同细分市场划分的心脏代谢疾病市场
亚太地区心脏代谢疾病市场细分
按类型
心血管疾病（CVD）
2 型糖尿病
高血压
肥胖
治疗
ACE抑制剂
利尿剂
格华止
其他
按剂量
片剂
注射
按给药途径

口服
静脉注射
最终用户
医院
诊所
家庭护理设置 ;
按分销渠道
医院药房
零售药房
在线药房
按国家/地区
亚太地区
中国
日本
印度
韩国
澳大利亚
亚太地区其他地区
提及的公司
礼来公司和公司。
拜耳股份公司
诺华公司             ;
勃林格殷格翰国际有限公司
诺和诺德公司
阿斯利康
Kowa Company, Ltd.
Cardax, Inc.

1.           Introduction 21
1.1         Scope of the Study. 21
1.2         The Insight Partners Research Report Guidance. 21
1.3         Market Segmentation. 23
1.3.7        Asia Pacific Cardiometabolic Diseases market – By Country. 25
2.           Asia Pacific Cardiometabolic Diseases Market – Key Takeaways 26
3.        Research Methodology 31
3.1         Coverage. 33
3.2         Secondary Research. 33
3.3         Primary Research. 34
4.           Asia Pacific Cardiometabolic Diseases Market – Market Landscape 35
4.1         Overview.. 35
4.2         PEST Analysis. 36
4.3         Expert Opinions. 37
5.           Asia Pacific Cardiometabolic Diseases Market – Key Market Dynamics 38
5.1         Market Drivers. 38
5.1.1        Increasing Prevalence of Cardiometabolic Diseases. 38
5.1.2        Innovation in Cardiometabolic Diseases Therapeutics. 38
5.2         Market Restraints. 39
5.2.1        Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs) 39
5.3         Market Opportunities. 40
5.3.1        Technological Advancements in CMD Diagnosis. 40
5.4         Future Trends. 40
5.4.1        Personalized Treatment for CMDs. 40
5.5         Impact Analysis. 41
6.           Asia Pacific Cardiometabolic Diseases Market – Regional Analysis 42
6.1         Asia Pacific Cardiometabolic Diseases Market Revenue Forecast And Analysis. 42
7.           Asia Pacific Cardiometabolic Diseases Market Analysis – By Type 44
7.1         Overview.. 44
7.2         Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028) 44
7.3         Cardiovascular Disease (CVD) 45
7.3.1        Overview.. 45
7.3.2        Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 46
7.4         Hypertension. 47
7.4.1        Overview.. 47
7.4.2        Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 47
7.5         Type 2 Diabetes. 48
7.5.1        Overview.. 48
7.5.2        Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 48
7.6         Obesity. 50
7.6.1        Overview.. 50
7.6.2        Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 50
8.           Asia Pacific Cardiometabolic Diseases Market Analysis – By Treatment 52
8.1         Overview.. 52
8.2         Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028) 52
8.3         ACE inhibitors. 53
8.3.1        Overview.. 53
8.3.2        ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn) 53
8.4         Diuretics. 55
8.4.1        Overview.. 55
8.4.2        Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 55
8.5         Glucophage. 56
8.5.1        Overview.. 56
8.5.2        Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 56
8.6         Others. 57
8.6.1        Overview.. 57
8.6.2        Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 57
9.           Asia Pacific Cardiometabolic Diseases Market Analysis – By Dosage 58
9.1         Overview.. 58
9.2         Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028) 58
9.3         Tablet 59
9.3.1        Overview.. 59
9.3.2        Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 59
9.4         Injection. 60
9.4.1        Overview.. 60
9.4.2        Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 60
10.        Asia Pacific Cardiometabolic Diseases Market Analysis – By Route of Administration 61
10.1      Overview.. 61
10.2      Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%) 61
10.3      Oral 62
10.3.1     Overview.. 62
10.3.2     Oral Market Revenue and Forecast to 2028 (US$ Mn) 62
10.4      Intravenous. 64
10.4.1     Overview.. 64
10.4.2     Intravenous Market Revenue and Forecast to 2028 (US$ Mn) 64
11.        Asia Pacific Cardiometabolic Diseases Market Analysis – By End User 66
11.1      Overview.. 66
11.2      Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%) 66
11.3      Clinic. 67
11.3.1     Overview.. 67
11.3.2     Clinic Market Revenue and Forecast to 2028 (US$ Mn) 67
11.4      Hospital 68
11.4.1     Overview.. 68
11.4.2     Hospital Market Revenue and Forecast to 2028 (US$ Mn) 68
11.5      Homecare Settings. 70
11.5.1     Overview.. 70
11.5.2     Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn) 70
12.        Asia Pacific Cardiometabolic Diseases Market Analysis – By Distribution Channel 72
12.1      Overview.. 72
12.2      Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%) 72
12.3      Hospital Pharmacy. 73
12.3.1     Overview.. 73
12.3.2     Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 73
12.4      Retail Pharmacy. 74
12.4.1     Overview.. 74
12.4.2     Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 74
12.5      Online Pharmacy. 76
12.5.1     Overview.. 76
12.5.2     Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 76
13.        Asia Pacific Cardiometabolic Diseases Market – Geographic Analysis 78
13.1      Asia Pacific: Cardiometabolic Diseases Market 78
13.1.1     Overview.. 78
13.1.2     Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 80
13.1.3     Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 81
13.1.4     Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 81
13.1.5     Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 82
13.1.6     Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 82
13.1.7     Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 83
13.1.8     Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 83
13.1.9     Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%) 84
13.1.9.1       China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 85
13.1.9.1.1       China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 86
13.1.10 China: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 86
13.1.11 China: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 87
13.1.12 China: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 87
13.1.13 China: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 88
13.1.14 China: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 88
13.1.15 China: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 89
13.1.15.1    Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 90
13.1.15.1.1    Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 90
13.1.16 Japan: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 91
13.1.17 Japan: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 92
13.1.18 Japan: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 92
13.1.19 Japan: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 93
13.1.20 Japan: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 93
13.1.21 Japan: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 94
13.1.21.1    India: Cardiometabolic Diseases Market - Revenue and Forecasts to 2028 (USD Million) 95
13.1.21.1.1    India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 96
13.1.22 India: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 97
13.1.23 India: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 97
13.1.24 India: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 98
13.1.25 India: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 98
13.1.26 India: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 99
13.1.27 India: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 99
13.1.27.1    South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 100
13.1.27.1.1    South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 100
13.1.28 South Korea: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 101
13.1.29 South Korea: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 102
13.1.30 South Korea: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 102
13.1.31 South Korea: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 103
13.1.32 South Korea: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 103
13.1.33 South Korea: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 104
13.1.33.1    Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 105
13.1.33.1.1    Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 105
13.1.34 Australia: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 106
13.1.35 Australia: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 107
13.1.36 Australia: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 107
13.1.37 Australia: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 108
13.1.38 Australia: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 108
13.1.39 Australia: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 109
13.1.39.1    Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 110
13.1.39.1.1    Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 110
13.1.40 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 111
13.1.41 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 112
13.1.42 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 112
13.1.43 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 113
13.1.44 Rest of Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 113
13.1.45 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 114
14.        Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market 115
14.1      Asia Pacific: Impact Assessment of COVID-19 Pandemic. 115
15.        Asia Pacific Cardiometabolic Diseases Market – Industry Landscape 117
15.1      Overview.. 117
15.2      Growth Strategies in the Cardiometabolic Diseases Market (%) 118
15.3      Organic Developments. 119
15.3.1     Overview.. 119
15.4      Inorganic Developments. 122
15.4.1     Overview.. 122
16.        Company Profiles 124
16.1      Eli Lilly and Company. 124
16.1.1     Key Facts. 124
16.1.2     Business Description. 124
16.1.3     Products and Services. 125
16.1.4     Financial Overview.. 127
16.1.5     SWOT Analysis. 130
16.1.6     Key Developments. 131
16.2      Bayer AG.. 134
16.2.1     Key Facts. 134
16.2.2     Business Description. 134
16.2.3     Products and Services. 135
16.2.4     Financial Overview.. 135
16.2.5     SWOT Analysis. 138
16.2.6     Key Developments. 139
16.3      Novartis AG.. 141
16.3.1     Key Facts. 141
16.3.2     Business Description. 141
16.3.3     Products and Services. 142
16.3.4     Financial Overview.. 143
16.3.5     SWOT Analysis. 146
16.3.6     Key Developments. 147
16.4      Boehringer Ingelheim International GmbH.. 148
16.4.1     Key Facts. 148
16.4.2     Business Description. 148
16.4.3     Products and Services. 149
16.4.4     Financial Overview.. 150
16.4.5     SWOT Analysis. 154
16.4.6     Key Developments. 155
16.5      Novo Nordisk A/S. 157
16.5.1     Key Facts. 157
16.5.2     Business Description. 157
16.5.3     Products and Services. 158
16.5.4     Financial Overview.. 159
16.5.5     SWOT Analysis. 162
16.5.6     Key Developments. 163
16.6      AstraZeneca. 165
16.6.1     Key Facts. 165
16.6.2     Business Description. 165
16.6.3     Products and Services. 166
16.6.4     Financial Overview.. 167
16.6.5     SWOT Analysis. 170
16.6.6     Key Developments. 171
16.7      Cardax, Inc. 173
16.7.1     Key Facts. 173
16.7.2     Business Description. 173
16.7.3     Products and Services. 174
16.7.4     Financial Overview.. 174
16.7.5     SWOT Analysis. 177
16.7.6     Key Developments. 177
16.8      Kowa Company, Ltd. 178
16.8.1     Key Facts. 178
16.8.2     Business Description. 178
16.8.3     Products and Services. 179
16.8.4     Financial Overview.. 179
16.8.5     SWOT Analysis. 180
16.8.6     Key Developments. 181
17.        Appendix 182
17.1      About The Insight Partners. 182
17.2      Glossary of Terms. 183
LIST OF TABLES
Table 1.             Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 81
Table 2.             Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 81
Table 3.             Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 82
Table 4.             Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 82
Table 5.             Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 83
Table 6.             Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 83
Table 7.             China Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 86
Table 8.             China Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 87
Table 9.             China Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 87
Table 10.          China Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 88
Table 11.          China Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 88
Table 12.          China Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 89
Table 13.          Japan Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 91
Table 14.          Japan Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 92
Table 15.          Japan Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 92
Table 16.          Japan Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 93
Table 17.          Japan Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 93
Table 18.          Japan Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 94
Table 19.          India Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 97
Table 20.          India Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 97
Table 21.          India Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 98
Table 22.          India Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 98
Table 23.          India Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 99
Table 24.          India Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 99
Table 25.          South Korea Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 101
Table 26.          South Korea Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 102
Table 27.          South Korea Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 102
Table 28.          South Korea Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 103
Table 29.          South Korea Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 103
Table 30.          South Korea Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 104
Table 31.          Australia Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 106
Table 32.          Australia Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 107
Table 33.          Australia Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 107
Table 34.          Australia Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 108
Table 35.          Australia Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 108
Table 36.          Australia Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 109
Table 37.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 111
Table 38.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 112
Table 39.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 112
Table 40.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 113
Table 41.          Rest of Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 113
Table 42.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 114
Table 43.          Organic Developments in the Cardiometabolic Diseases Market 119
Table 44.          Inorganic Developments in the Cardiometabolic Diseases Market 123
Table 45.          Glossary of Terms, Asia Pacific Cardiometabolic Diseases Market 183

LIST OF FIGURES
Figure 1.           Asia Pacific Cardiometabolic Diseases Market Segmentation. 23
Figure 2.           Asia Pacific Cardiometabolic Diseases Market Overview.. 26
Figure 3.           Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Asia Pacific Cardiometabolic Diseases Market 27
Figure 4.           Asia Pacific Cardiometabolic Diseases Market – Leading Country Markets (US$ Million) 28
Figure 5.           Asia Pacific Cardiometabolic Diseases Market, Industry Landscape. 29
Figure 6.           Asia Pacific PEST Analysis. 36
Figure 7.           Asia Pacific Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints. 41
Figure 8.           Asia Pacific Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028. 43
Figure 9.           Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028) 44
Figure 10.        Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 46
Figure 11.        Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 47
Figure 12.        Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 49
Figure 13.        Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 51
Figure 14.        Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028) 52
Figure 15.        ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 54
Figure 16.        Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 55
Figure 17.        Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 56
Figure 18.        Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 57
Figure 19.        Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028) 58
Figure 20.        Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 59
Figure 21.        Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 60
Figure 22.        Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%) 61
Figure 23.        Oral Market Revenue and Forecasts to 2028 (US$ Mn) 63
Figure 24.        Intravenous Market Revenue and Forecasts to 2028 (US$ Mn) 65
Figure 25.        Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%) 66
Figure 26.        Clinic Market Revenue and Forecasts to 2028 (US$ Mn) 67
Figure 27.        Hospital Market Revenue and Forecasts to 2028 (US$ Mn) 69
Figure 28.        Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn) 71
Figure 29.        Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%) 72
Figure 30.        Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 73
Figure 31.        Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 75
Figure 32.        Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 77
Figure 33.        Asia Pacific: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million) 79
Figure 34.        Asia Pacific Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million) 80
Figure 35.        Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%) 84
Figure 36.        China Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 86
Figure 37.        Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 91
Figure 38.        India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 96
Figure 39.        South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 101
Figure 40.        Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 106
Figure 41.        Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 111
Figure 42.        Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market 116
Figure 43.        Growth Strategies in the Cardiometabolic Diseases Market (%) 118

Eli Lilly and Company.
Bayer AG
Novartis AG
Boehringer Ingelheim International Gmbh
Novo Nordisk A/S
AstraZeneca
Kowa Company, Ltd.
Cardax, Inc.

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific cardiometabolic diseases market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Report Code

Full Name

Country Name

Email Id

Phone Number

Job Title

Company

Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports

Report Name Published Date

Asia Pacific Wind Turbine Condition Monitoring Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Component (Hardware, and Software an.. May 2022

Asia Pacific Automotive System Simulation Software Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Transmission, Engine, Elec.. May 2022

Asia Pacific Ground Engaging Tools Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Application (Excavators, Loaders, Bulldozers, an.. May 2022

Report Name	Published Date
Asia Pacific Wind Turbine Condition Monitoring Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Component (Hardware, and Software an..	May 2022
Asia Pacific Automotive System Simulation Software Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Transmission, Engine, Elec..	May 2022
Asia Pacific Ground Engaging Tools Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Application (Excavators, Loaders, Bulldozers, an..	May 2022

Purchase Options

Single User License

$3000

$1800

Site License

$4000

$2400

Enterprise License

$5000

$3000

GET FREE SAMPLE PDF
Inquire before Buying Inquire for Discount

Subscription Member Price: FREE
Get Subscription

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

Request for Free Sample

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.